Skip to main content
VCbacked
Log inGet Started

LOQUS23 THERAPEUTICS

London, United Kingdom

LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington's disease.

$46.4M raised
Oct 2024
Series A
Biotechnology

Top Investors

SV Health InvestorsDementia Discovery FundForbion Capital PartnersNovartis Venture Fund

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about LOQUS23 THERAPEUTICS

How much funding has LOQUS23 THERAPEUTICS raised?
LOQUS23 THERAPEUTICS has raised $46.4M in total funding. The most recent round was Series A. The last funding was announced in October 2024.
Who are LOQUS23 THERAPEUTICS's investors?
LOQUS23 THERAPEUTICS's investors include SV Health Investors, Dementia Discovery Fund, Forbion Capital Partners, Novartis Venture Fund.
Where is LOQUS23 THERAPEUTICS headquartered?
LOQUS23 THERAPEUTICS is headquartered in London, United Kingdom.
What does LOQUS23 THERAPEUTICS do?
LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington's disease.
What stage is LOQUS23 THERAPEUTICS at?
LOQUS23 THERAPEUTICS is at the Series A stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"LOQUS23 THERAPEUTICS — Funding & Investors." VCBacked, October 2, 2024, https://www.vcbacked.co/company/loqus23-therapeutics. Accessed June 17, 2026.
APA
VCBacked. (2024). LOQUS23 THERAPEUTICS — Funding & Investors. Retrieved June 17, 2026, from https://www.vcbacked.co/company/loqus23-therapeutics
Wikipedia (cite web)
{{cite web |title=LOQUS23 THERAPEUTICS — Funding & Investors |url=https://www.vcbacked.co/company/loqus23-therapeutics |website=VCBacked |access-date=June 17, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biotechnology

View all
Virtuoso Surgical
Nashville
Pharvaris
Zug
Odyssey Therapeutics
Boston$213.0M
Tempus
Chicago
Anagram Therapeutics
Boston
Prenetics
Hong Kong